Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth.

Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth.
复制标题

DOI:
10.1002/cpt.2083
复制
发表时间:
2021-05
影响因子:
6.7
通讯作者:
Rasi G
Rasi G
中科院分区:
医学2区
文献类型:
--
作者:
Eichler HG;Pignatti F;Schwarzer-Daum B;Hidalgo-Simon A;Eichler I;Arlett P;Humphreys A;Vamvakas S;Brun N;Rasi G

文献摘要

参考文献

被引文献

相似文献

与重磅炸弹时代的药物相比,最近批准的药物和那些预计将在未来使用的药物呈现出化学、生物制剂以及细胞和基因疗法的异质组合,其中相当大一部分是针对罕见疾病的,甚至是个性化的治疗或个性化的组合。产品性质的转变导致了“药物”和“目标人群”的定义以及临床使用和证据生成的长期趋势。我们讨论了从20世纪医学的证据生成中学到的经验教训对21世纪医学的相关性可能有限。我们解释了为什么未来不是关于随机对照试验(RCT)与真实世界证据(RWE),而是RCT和RWE--不仅是为了评估安全性,也是为了评估有效性。最后,我们强调,在精准医学时代,我们可能无法可靠地描述一些微小的治疗效果--无论是通过随机对照试验还是通过随机对照试验。
Compared with drugs from the blockbuster era, recently authorized drugs and those expected in the future present a heterogenous mix of chemicals, biologicals, and cell and gene therapies, a sizable fraction being for rare diseases, and even individualized treatments or individualized combinations. The shift in the nature of products entails secular trends for the definitions of “drugs” and “target population” and for clinical use and evidence generation. We discuss that the lessons learned from evidence generation for 20th century medicines may have limited relevance for 21st century medicines. We explain why the future is not about randomized controlled trials (RCTs) vs. real‐world evidence (RWE) but RCTs and RWE—not just for the assessment of safety but also of effectiveness. Finally, we highlight that, in the era of precision medicine, we may not be able to reliably describe some small treatment effects—either by way of RCTs or RWE.
DOI: 10.1002/cpt.515
发表时间: 2016-12
影响因子: 6.7
作者:
Eichler, H-G;Bloechl-Daum, B.;Bauer, P.;Bretz, F.;Brown, J.;Hampson, L. V.;Honig, P.;Krams, M.;Leufkens, H.;Lim, R.;Lumpkin, M. M.;Murphy, M. J.;Pignatti, F.;Posch, M.;Schneeweiss, S.;Trusheim, M.;Koenig, F.
通讯作者: Koenig, F.
DOI: 10.1002/cpt.1226
发表时间: 2019-04
影响因子: 6.7
作者:
Eichler HG;Bloechl-Daum B;Broich K;Kyrle PA;Oderkirk J;Rasi G;Santos Ivo R;Schuurman A;Senderovitz T;Slawomirski L;Wenzl M;Paris V
通讯作者: Paris V
DOI: 10.1056/nejmoa1409547
发表时间: 2015-07-16
期刊: The New England journal of medicine
影响因子: --
作者:
Wainwright CE;Elborn JS;Ramsey BW;Marigowda G;Huang X;Cipolli M;Colombo C;Davies JC;De Boeck K;Flume PA;Konstan MW;McColley SA;McCoy K;McKone EF;Munck A;Ratjen F;Rowe SM;Waltz D;Boyle MP;TRAFFIC Study Group;TRANSPORT Study Group
通讯作者: TRANSPORT Study Group
DOI: 10.1186/s13023-019-1017-5
发表时间: 2019-02-08
影响因子: 3.7
作者:
Mulberg, Andrew E.;Bucci-Rechtweg, Christina;Kessler, Vivian
通讯作者: Kessler, Vivian
DOI: 10.1038/onc.2008.170
发表时间: 2008-09-18
期刊: ONCOGENE
影响因子: 8
作者:
Bleeker, F. E.;Felicioni, L.;Bardelli, A.
通讯作者: Bardelli, A.